TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06240806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manuka Honey
Description: Manuka honey will be topically applied to the oral mucosa as oral rinse based on the Biswal et al., 2003 administration protocol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline mouthwash
Description: Saline mouthwash will be used 3 times per day for one month
Study: NCT04763850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decline Walking with real-time Feedback
Description: Participants are walking decline with self-paced speed on an instrumented treadmill with virtual reality projection under three conditions: without instruction, with instruction for an internal focus of attention and with real-time feedback of their frontal knee alignment
Study: NCT05960500

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant
Description: All on six versus parallel implant distribution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant
Description: All on six versus parallel implant distribution
Study: NCT06196762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XKH002 Injection
Description: 240 mg/4 mL/vial（60 mg/mL）
Study: NCT05974969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-264
Description: a single intravenous infusion of BCD-264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darzalex
Description: a single intravenous infusion of Darzalex
Study: NCT04454411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brixadi
Description: Extended release injectable Buprenorphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vivitrol
Description: Extended release injectable Naltrexone
Study: NCT06435234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: risky sexual behavior intervention
Description: Intervening in risky sexual behaviors among college students
Study: NCT05099068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood and tumor samples
Description: Longitudinal molecular profiling of tumor and liquid biopsies.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood and tumor samples
Description: Longitudinal molecular profiling of tumor and liquid biopsies.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood and tumor samples
Description: Longitudinal molecular profiling of tumor and liquid biopsies.
Study: NCT05635994

Intervention type: DIAGNOSTIC_TEST
Intervention: AID strategy
Description: AID strategy encompasses a hierarchical algorithm intended to investigate both obstructive and non-obstructive causes of myocardial ischaemia. AID strategy starts with an ICA. Angiographically severe-grade stenosis (≥70%) can be safely considered flow-limiting without further physiological assessment. Conversely, by means of a pressure guidewire, intermediate-grade stenosis should be evaluated with FFR and/or NHPR in order to determine if they are physiologically significant. Those patients with non-obstructive CAD or normal epicardial coronary arteries should undergo functional coronary tests to investigate the presence of microcirculatory and vasomotor coronary disorders, which would account for non-obstructive causes of ischaemia.
Study: NCT05849220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study: NCT05678621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole (co-trimoxazole)
Description: Doxycycline is an alternative for participants with hypersensitivity to co-trimoxazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxycillin/clavulanic acid and ciprofloxacin
Description: clindamycin is an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunoglobulins
Description: Intravenous monthly immunoglobulin or subcutaneous weekly immunoglobulin
Study: NCT04809779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: The PD-1 inhibitor Sintilimab 200mg for intravenous (IV) administration will be given together with three-week epirubincin, cyclophosphamide (EC) × 4 treatments from the second cycle followed by weekly nab-paclitaxel x12 treatments or three-week nab-paclitaxel x4 treatments.
Study: NCT04859855

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restrictive transfusional strategy
Description: Transfusion of Red Blood Concentrates (RBCs) if Hb ≤7,0g/dL with the aim of maintaining Hb levels between 7,0-9,0g/dL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liberal transfusional strategy
Description: Transfusion of RBC if Hb ≤9,0g/dL, with the aim of maintaining Hb levels between 9,0-10,0g/dL
Study: NCT05044403

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal support with haemoperfusion
Description: Use of extracorporeal support with haemoperfusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment
Study: NCT06000189

Intervention type: PROCEDURE
Intervention: Standardized skin surface biopsies (SSSB)
Description: Skin samples will be obtained from four regions of the participants' faces, including the forehead, right cheek, left cheek, and the nose, before phototherapy and after 20 sessions of phototherapy. The SSSB will be performed as follows: a 1 cm² square will be drawn on a glass slide using a ruler. The skin areas to be sampled will be gently swabbed with a dry gauze to induce irritation by this way to obtain more mites. Then, one drop of cyanoacrylate adhesive will be dropped onto the marked area on the glass slide, and the adhesive surface of the slide will be pressed onto the skin surface for approximately one minute. Afterwards, the slide will be gently lifted, and the sampled area will be examined under a light microscope at x10 and x40 magnifications after applying immersion oil. The presence of more than five Demodex mites per square centimeter will be defined as increased Demodex density.
Study: NCT06502041

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MARPE with MOP
Description: mini-screw assisted rapid palatal expansion with micro-osteoperforation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MARPE without MOP
Description: mini-screw assisted rapid palatal expansion without micro-osteoperforation
Study: NCT05926882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Patients will be given Oral Apremilast 30 mg twice daily after 05 days titration dose.
Study: NCT06442683

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TTE simulation-based medical training
Description: half-day simulation-based neonatal echocardiography training.
Study: NCT05736237

Intervention type: GENETIC
Intervention: Whole exome sequencing
Description: With Next Generation Sequenzing
Study: NCT04694300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: 440 mg by mouth immediately after completion of implant surgery followed by 220 mg 12 hours later.~Then 220 mg every 8 hours for the next two days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg by mouth immediately after the completion of implant surgery followed by 1000 mg every 6 hours for 3 days after surgery with a maximum daily dose of 3000 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 50 mg by mouth every 6 hours as needed for pain
Study: NCT05041335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wet heparinzed suction
Description: Needle flushed with 5000 Units in 10mL of heparin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wet heparinzed suction
Description: Needle flushed with 5000 Units in 10mL of heparin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microsieve
Description: A microsieve used for tissue preparation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microsieve
Description: A microsieve used for tissue preparation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No heparin flush
Description: The needle not prepped

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No heparin flush
Description: The needle not prepped

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No microsieve
Description: The tissue is placed into formalin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No microsieve
Description: The tissue is placed into formalin
Study: NCT06454357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B007
Description: B007：high dose/low dose: Subcutaneous injection was administered on days 1 and 15
Study: NCT05567328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Research FibroScan (FS)
Description: Exams will be performed with the M or XL probe as per FS recommendations. Same probe must be used for all exams Exploratory exam after patient 151 are performed with adapted view of Research FS~Patients 1 to 90 \& 151 to 190 Exam1 Exploratory exam with the Research FS Exam2 Reference exam with the CE-marked FS~Patients 91 to 130 \& 191 to 230 Exams1\&2 Two consecutive Exploratory exams with the Research FS Exams3\&4 Two consecutive Reference exams with the CE-marked FS~Patients 131 to 150 Exams1\&2 Two consecutive Exploratory exams with automatic function of the Research FS Exam3 Reference exam with the CE-marked FS~Patients 231 to 270 Exams1 (novice operator) Exploratory exam with the Research FS Exams2 (novice operator) Reference exam with the CE-marked FS Exams3 (experienced/expert operator) Exploratory exam with the Research FS Exams4 (experienced/expert operator) Reference exam with the CE-marked FS
Study: NCT05958017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reSET
Description: Participants in this group will use a mobile application that delivers treatment for substance use disorder. 31 required and 30 optional modules. Among many topics covered in the modules, some are substance use management, communication, emotion management, relationship skills, HIV/Sexually Transmitted Infections and triggers for risky sex. In the reSET app you will get the chance to earn rewards for two activities: (1) completing a module and (2) providing a negative urine drug screen in exchange for a motivational or monetary prize. You will have 12 weeks to complete as many modules as you like, about 4 modules per week. Each module takes approximately 10-15 min. Every 3-4 days you will meet with the same study team member to provide a urine drug screen from a place comfortable for you (e.g. home) which will be observed and read via Zoom.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Participants in this group will receive assistance connecting to an in person community-based outpatient treatment program.
Study: NCT05566379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness - Mindful Awareness Practices ( MAPs)
Description: All participants will attend a virtual 6-week course entitled Mindful Awareness Practices (MAPs) created, hosted and led by expert facilitators from the Mindful Awareness Research Center at UCLA. Participants will learn Mindful concepts and a variety of Mindfulness practices. This intervention will consist of a mix of lecture, practice, group feedback, and discussion regarding mindfulness. Mindfulness is the mental state achieved by focusing one's awareness on the present while acknowledging and accepting any feelings, thoughts, or bodily sensations. MAPs classes meets weekly for two hours per week for six weeks. Participants are encouraged to complete some daily meditation practice starting at five minutes a day and working up to 20 minutes daily by the end of the course.
Study: NCT04927780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Open or minimally-invasive pancreatectomy.
Study: NCT05822700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kirschner wire
Description: Transfixing femoral head Kirschner wire
Study: NCT05031481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venus 20 + 0,064
Description: Venus vaginal cream 20 + 0,064, single-dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venus 20 + 1
Description: Venus vaginal cream 20 + 1, single-dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venus 20 + 4
Description: Venus vaginal cream 20 + 4, single-dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Butoconazole nitrate
Description: Butoconazole nitrate vaginal cream, 100 mg single-dose.
Study: NCT04934514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IAH0968
Description: IAH0968 is an investigational product.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IAH0968
Description: IAH0968 is an investigational product.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IAH0968
Description: IAH0968 is an investigational product.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IAH0968
Description: IAH0968 is an investigational product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 intravenous infusion
Study: NCT04839224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbogen
Description: Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine
Description: Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
Study: NCT06441266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KeraStat cream
Description: KeraStat Cream is a non-sterile, non-implantable, emollient-based wound dressing intended to act as a protective covering in the management of a variety of skin conditions. The intervention is a topical cream applied at least twice daily starting at start of radiation therapy until 1-month from the end of radiation therapy completion
Study: NCT04756141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: A CGM will be placed on patients with diabetes mellitus and COVID-19 infection and interstitial glucose will be monitored continuously while the patients are in the hospital.
Study: NCT06441266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M-PART Assessments via MyCap
Description: The M-PART approach harnesses the remote data collection capabilities of MyCap to facilitate remote collection or data including but not limited to toxicity assessments, quality of life surveys, and patient-provided photographs of the skin in the treated area

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Assessments
Description: Participants will undergo assessments at baseline (prior to radiation therapy start), weekly during and after radiation therapy until 1-month post-radiation therapy. Medical history will be collected at baseline including primary cancer site, HPV status (if oropharyngeal cancer primary), laterality, TNM classification, stage, surgical resection prior to radiation therapy, weight, body mass index and patient self-reported Fitzpatrick skin phototype.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback phone interview
Description: Participant satisfaction, perceptions and preferences with using M-PART will be discussed.
Study: NCT06161597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up Online
Description: Families will be provided with access to the FCO program, available in English or Spanish. Parents complete a tutorial and five different modules focused on distinct parenting skills. Each module starts with a survey and feedback to help identify relative strengths and challenges with the targeted parenting skills. Parents are then guided through various online activities including videos that model right and wrong ways to handle comm on situations and explanations of parental self-management and problem-solving strategies. Parents are complete activities to practice the parenting skills taught. Parents will have access to the online program for 8 and they are encouraged to practice the program strategies during this time period. At the end of the 8 weeks, parent re-complete the brief questions that they filled out at the beginning of each module and then receive feedback indicating which of the parent's domain scores have improved since they completed each module.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up Online
Description: Families will be provided with access to the FCO program, available in English or Spanish. Parents complete a tutorial and five different modules focused on distinct parenting skills. Each module starts with a survey and feedback to help identify relative strengths and challenges with the targeted parenting skills. Parents are then guided through various online activities including videos that model right and wrong ways to handle comm on situations and explanations of parental self-management and problem-solving strategies. Parents are complete activities to practice the parenting skills taught. Parents will have access to the online program for 8 and they are encouraged to practice the program strategies during this time period. At the end of the 8 weeks, parent re-complete the brief questions that they filled out at the beginning of each module and then receive feedback indicating which of the parent's domain scores have improved since they completed each module.
Study: NCT06404697

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost irradiation
Description: High-risk patients will undergo boost irradiation to the SCV with a cumulative dose of ≥60 Gy.
Study: NCT04758871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 10 MG Oral Tablet
Description: 10 mg three times daily
Study: NCT05776225

Intervention type: PROCEDURE
Intervention: Right heart catheterization (RHC)
Description: RHC to evaluate pulmonary hemodynamics
Study: NCT06046001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirWaze
Description: AirWaze - easy and advanced tools for CBCT guided lung interventions
Study: NCT06457503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Participants will receive toripalimab via intravenous infusion (IV) on Day 1 every 3 weeks (Q3W) during the Chemotherapy-based treatment phase and Maintenance treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive cisplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive gemcitabine via IV on Day 1 and Day 8 Q3W during the Chemotherapy-based treatment phase.
Study: NCT04758871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized progesterone
Description: 2x 200 mg vaginal tablets two times daily
Study: NCT05480618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow Breathing
Description: On two separate visits (on Day 1 and between Day 7 and 9 of their self-practice) the subject will be coached on yoga breathing techniques.~The breathing techniques will be varied in:~1. frequency (between 0.25 and 0.1 Hz)~2. Inspiratory:Expiratory (I:E) ratio or 'Duty Cycle'~3. with and without ujjayi (yogic throat restriction)~4. with and without inspiratory/expiratory breath holding~At the end of the first coaching visit the subject will be given a diary to record their own practice of the breathing techniques they were coached on.
Study: NCT05593406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration Group
Description: Whole body vibration for 15 minutes in squat and lunge position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: NDT treatment 2 sessions per week
Study: NCT04927780

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection
Description: Open or minimally-invasive pancreatectomy.
Study: NCT04694300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: 50 mg by mouth every 6 hours as needed for pain
Study: NCT05446090

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry including peak flow
Description: Spirometry including peak flow to assess the degree of airway obstruction. Spirometry will be conducted according to a study SOP. The Global Lung Function (GLI) 2012 equations will be used. Reversibility testing will not be routinely performed. Thus, asthma medications will not normally be withheld for study visits and patients should take their inhalers as usual. The same type of device will be used at each visit.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fractional Exhaled Nitric Oxide (FeNO)
Description: Fractional Exhaled Nitric Oxide (FeNO) to assess the degree of airway inflammation. FeNO will be measured using a standard device (NIOXX Vero®) in accordance with the manufacturer's guidelines. The same type of device will be used at each visit. FeNO should be performed prior to any other respiratory assessment if possible.

Intervention type: DIAGNOSTIC_TEST
Intervention: Forced Oscillation Technique (FOT)
Description: FOT is a non-invasive method that evaluates resistance and reactance in the respiratory system during tidal breathing. It should be performed after FeNO, but prior to Spirometry and will be conducted according to a study SOP.

Intervention type: PROCEDURE
Intervention: Sputum Induction
Description: Sputum Induction for the assessment of airway inflammation and microbiology. Sputum induction will be performed according to an SOP, which includes measures to protect the safety of participants. These consist of pre-treatment with Salbutamol, a short acting bronchodilator, stipulated levels of lung function in order to perform the test and stopping criteria. If the participant is unable to undergo the procedure, due to safety reasons, they will be asked to produce a spontaneous sputum sample. Sputum samples will be collected for a differential cell count, bacterial culture and sensitivity and storage for future research. Procedures for sampling and processing will be detailed in a study SOP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bloods
Description: Blood will be collected for laboratory analysis, including Vitamin D, Haematology, WCC differential, C-Reactive protein.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal lavage
Description: Nasal lavage samples will be taken at the baseline (attack) visit. Samples will be obtained by injecting 5ml of sterile normal saline into the participant's nostrils via a nasal adaptor and then immediately aspirated. These will be placed in a sterile container and transported to the laboratory for viral identification. This procedure will be detailed in a study SOP.